Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,460.77 -8.53 (-0.16%) Dow
38,973.93 -138.23 (-0.35%) Nasdaq
17,753.99 +36.34 (+0.21%) Bitcoin USD
61,671.63 -290.77 (-0.47%) CMC Crypto 200
1,281.42 -2.37 (-0.18%)
Day One Biopharmaceuticals, Inc. (DAWN)
- GuruFocus.com
Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) on June 21, 2024, as reported in a recent SEC Filing.
- GlobeNewswire
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threat
- Fortune
Exclusive: Day One Ventures closes its third fund at $150 million
Bucher’s Day One has closed its third fund at $150 million, Fortune can exclusively report. That far surpasses the firm’s original $100 million target, and I can only find one fund raised by a female solo GP this year that’s bigger.
